Collegium Pharmaceutical (NASDAQ:COLL) Downgraded by Zacks Research to “Strong Sell”

Zacks Research lowered shares of Collegium Pharmaceutical (NASDAQ:COLL) from a hold rating to a strong sell rating in a research note published on Tuesday morning,Zacks reports.

Other equities research analysts have also issued reports about the company. Needham & Company LLC cut their price objective on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Leerink Partners assumed coverage on Collegium Pharmaceutical in a report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 target price for the company. Wall Street Zen lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings cut shares of Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, September 4th. Finally, Oppenheimer assumed coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $50.00 price target on the stock. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $48.71.

Collegium Pharmaceutical Stock Performance

Collegium Pharmaceutical stock opened at $21.93 on Tuesday. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32. The firm has a 50-day moving average of $25.68 and a 200-day moving average of $31.38. The firm has a market cap of $714.04 million, a P/E ratio of 17.69, a P/E/G ratio of 0.70 and a beta of 0.73. Collegium Pharmaceutical has a 1-year low of $21.43 and a 1-year high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $199.88 million for the quarter, compared to the consensus estimate of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.Collegium Pharmaceutical’s revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.68 EPS. Sell-side analysts expect that Collegium Pharmaceutical will post 6.21 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in Collegium Pharmaceutical during the second quarter valued at $196,972,000. Jupiter Topco LLC bought a new position in shares of Collegium Pharmaceutical in the 2nd quarter worth about $77,743,000. Janus Henderson Group PLC increased its stake in shares of Collegium Pharmaceutical by 26.0% in the 1st quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company’s stock worth $60,358,000 after acquiring an additional 377,073 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Collegium Pharmaceutical by 0.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 833,192 shares of the specialty pharmaceutical company’s stock worth $27,551,000 after acquiring an additional 2,712 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in Collegium Pharmaceutical by 29.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 703,528 shares of the specialty pharmaceutical company’s stock valued at $23,266,000 after acquiring an additional 159,755 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing, acquiring and commercializing medicines for central nervous system disorders. The company’s portfolio is concentrated in pain management and includes products for chronic and acute pain, opioid-induced constipation and related conditions.

Collegium’s marketed products include Xtampza ER, an extended-release oxycodone formulation designed with the company’s DETERx abuse-deterrent technology; Nucynta and Nucynta ER, tapentadol products for acute and chronic pain; Belbuca, a buprenorphine buccal film for chronic pain; and Symproic, a treatment for opioid-induced constipation.